Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.

Saved in:
Bibliographic Details
Title: Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Authors: Hummel HD; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany., Kufer P; Research and Development, Amgen Research Munich GmbH, Staffelseestr. 2, 81477, Munich, Germany., Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany; & Department of Oncology & Hematology, University Hospital Dresden, Haus 27, Fetscherstr. 74, 01307 Dresden, Germany., Seggewiss-Bernhardt R; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany.; Medizinische Klinik V, Sozialstiftung Bamberg, Buger Str. 80, 96049, Bamberg, Germany., Deschler-Baier B; Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Josef-Schneider-Str. 6, 97080 Würzburg, Germany., Chatterjee M; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany., Goebeler ME; Translational Oncology/Early Clinical Trial Unit (ECTU), Medizinische Klinik II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany., Miller K; Department of Urology, Charité Universitätsmedizin Berlin, Charitéplatz. 1, 10117, Berlin, Germany., de Santis M; Department of Urology, Charité Universitätsmedizin Berlin, Charitéplatz. 1, 10117, Berlin, Germany.; Department of Urology, Medical University Vienna, Währinger Gürtel 18-20; 1090 Vienna, Austria., Loidl W; Department of Urology, Ordensklinikum Linz GmbH Elisabethinen, Fadingerstr. 1, 4020, Linz, Austria., Dittrich C; Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna) & Center for Oncology & Hematology, Kaiser Franz Josef-Spital, Bernardgasse 24/2, 1070, Vienna, Austria., Buck A; Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany., Lapa C; Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany.; Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany., Thurner A; Department of Diagnostic & Interventional Radiology, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany., Wittemer-Rump S; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Koca G; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Boix O; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Döcke WD; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Finnern R; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Kusi H; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Ajavon-Hartmann A; Bayer AG, SBU Oncology, Pharmaceuticals, 13353, Berlin, Germany., Stienen S; Research and Development, Amgen Research Munich GmbH, Staffelseestr. 2, 81477, Munich, Germany., Sayehli CM; Translational Oncology/Early Clinical Trial Unit (ECTU), Medizinische Klinik II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany., Polat B; Department of Radiation Oncology, University Hospital Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Germany., Bargou RC; Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Josef-Schneider-Str. 6, 97080 Würzburg, Germany.
Source: Immunotherapy [Immunotherapy] 2021 Feb; Vol. 13 (2), pp. 125-141. Date of Electronic Publication: 2020 Nov 10.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1750-7448
DOI:10.2217/imt-2020-0256